Intra-Arterial Delivery of Idarubicin in Two Patients with Glioblastoma

Mohamad Chehimi (1) , Mathieu Boone (2, 3) , Cyril Chivot , Herve Deramond (4) , Jean-Marc Constans (5) , Mony Chenda Ly , Bruno Chauffert (2, 3)

1 UPJV - Université de Picardie Jules Verne
2 CHU Amiens-Picardie
3 CHIMERE - CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516
4 Service de Radiologie [Amiens]
5 Service de Radiologie [CHU Caen]

There is no effective treatment for recurrent glioblastoma (GB) when temozolomide-based radiochemotherapy fails. In theory, intra-arterial (IA) delivery of cytotoxic agents could achieve higher drug concentrations in tumors compared to intravenous injection. Moreover, choosing a highly lipid-soluble drug could make the most of the first-pass effect. Here, we evaluated idarubicin (IDA), a lipophilic anthracycline, in an in vitro assay using four human GB cell lines and compared it with 11 other drugs previously used for the IA treatment of brain tumors. Despite impressive in vitro cytotoxicity, IA IDA did not produce a beneficial effect in 2 patients with recurrent GB. (C) 2016 The Author(s) Published by S. Karger AG, Basel

Domaines: Sciences du Vivant [q-bio]

Mohamad Chehimi, Mathieu Boone, Cyril Chivot, Herve Deramond, Jean-Marc Constans, et al.. Intra-Arterial Delivery of Idarubicin in Two Patients with Glioblastoma. Case Reports in Oncology, 2016, 9 (2), pp.499-505. ⟨10.1159/000448654⟩. ⟨hal-03598687⟩